Intellia Therapeutics (NTLA) Amortizatization of Intangibles (2019 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Amortizatization of Intangibles of $535000.0 for Q1 2026, down 76.54% year-over-year from $2.3 million in Q1 2025, and down 35.23% quarter-over-quarter from $826000.0 in Q4 2025.
Powered by 
Analysis
Intellia Therapeutics (NTLA) Amortizatization of Intangibles (2019 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Amortizatization of Intangibles for 8 consecutive years, with $535000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 76.54% year-over-year to $535000.0; the TTM figure through Mar 2026 stood at $4.1 million (down 72.23% YoY), while the FY2025 annual figure was $5.9 million, down 67.12% from the prior year.
- Amortizatization of Intangibles declined to $535000.0 in Q1 2026 per NTLA's latest filing, from $826000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $7.9 million in Q3 2023 and bottomed at -$2.4 million in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $2.7 million across 5 years, with a median of $2.3 million in 2025.
- Annual changes were most pronounced in 2022 — Amortizatization of Intangibles plunged 100.66% — and 2023, when it soared 1061.53%.
- Intellia Therapeutics' Amortizatization of Intangibles stood at $1.2 million in 2022, then jumped by 404.96% to $6.3 million in 2023, then sank by 42.89% to $3.6 million in 2024, then plunged by 77.07% to $826000.0 in 2025, then sank by 35.23% to $535000.0 in 2026.
- Business Quant data shows NTLA's Amortizatization of Intangibles at $535000.0 in Q1 2026, $826000.0 in Q4 2025, and $1.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Intellia Therapeutics | 1.70 Bn | 1.70 Bn | - | 614,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 614,000.00 |
| Mar 31, 2026 | 535,000.00 |
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Mar 31, 2025 | 2.28 Mn |
| Dec 31, 2024 | 3.60 Mn |
| Sep 30, 2024 | 4.28 Mn |
| Jun 30, 2024 | 4.65 Mn |
| Mar 31, 2024 | 5.29 Mn |
| Dec 31, 2023 | 6.31 Mn |
| Sep 30, 2023 | 7.92 Mn |
| Jun 30, 2023 | 7.10 Mn |
| Mar 31, 2023 | 4.57 Mn |
| Dec 31, 2022 | 1.25 Mn |
| Sep 30, 2022 | -824,000.00 |
| Jun 30, 2022 | -2.00 Mn |
| Mar 31, 2022 | -2.43 Mn |
| Dec 31, 2021 | -2.63 Mn |
| Sep 30, 2021 | -2.10 Mn |